by Elena Iemma | Mar 29, 2024 | Featured, News
PROVIDENCE, RI, April 1, 2024 /PRNewswire/ — Read the publication. In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk –...
by Elena Iemma | Mar 26, 2024 | Thinking Out Loud -Blog
OK, sometimes, I am late to the party. Maybe … allowing ideas, like parties, to mature, means getting there at exactly the right time. That just happened with this article and I’d like to share it with you. It’s about Tregitopes, even though the...
by Elena Iemma | Mar 5, 2024 | Events
Thank you to all who attended to the premier AI / HI & Immunoinformatics Workshop! The day was a huge success, and we couldn’t have done it without our amazing speakers and organizers. See pictures from the Workshop below and watch out for more EpiVax...
by Elena Iemma | Jun 27, 2023 | Uncategorized
Developing biologics? EpiVax’s High Throughput Immunogenicity Assessment provides a comprehensive assessment of potential clinical immunogenicity for large sets of biologic candidates. This approach allows preclinical researchers to compare the immunogenic...
by Elena Iemma | May 17, 2023 | Featured, News
PROVIDENCE, RI, May 17, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition,...